Pharma Leads in Sustainability - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharma Leads in Sustainability
A new report places pharmaceutical and healthcare companies ahead in corporate and social governance.


Pharmaceutical Technology
Volume 35, Issue 7, pp. 14


Angie Drakulich
Sustainability is about more than going green. When it comes to business strategy, it also includes social and corporate governance, according to a definition from consulting firm Brandlogic and investment analytics firm CRD Analytics. The companies recently released a survey about the real and perceived sustainability efforts of the top 100 companies around the world. The goal of the Sustainability Leadership Report: Measuring Perception vs. Reality is for industry to use the identified gaps between real and perceived sustainability efforts to improve corporate performance.

The good news is that the pharmaceutical/healthcare industry, one of nine sectors included in the survey, is leading the way in corporate sustainability. Other sectors included consumer, energy, financials, industrials and transportation, information technology, materials and mining, and telecommunications and Internet. The study authors used data from survey participants to establish a sustainability IQ matrix which groups companies into one of four areas: laggards (low perception, low reality), promoters (high perception, low reality), challengers (low perception, high reality), and leaders (high perception, high reality). Groups are based on real and perceived scores, both of which incorporate key performance indicators such as the company's environmental emissions, social diversity, and corporate vision.

Abbott Laboratories, AstraZeneca, Bayer, GlaxoSmithKline, Johnson & Johnson, Merck, Novo Nordisk, and Pfizer all ranked in the "leader" category. Roche fell into the "challenger" category; BASF fell into the "promoter" category; and no one from pharma ended up in the "laggard" field.

The industry's activities in environmental, social, and corporate governance come as no surprise. The most nascent goal of the drug-manufacturing world is to improve health, and ultimately, to improve lives. More and more, industry is realizing that social, environmental, and governance sustainability initiatives—and not just its products—can help it achieve this goal.

Angie Drakulich is the senior managing editor of Pharmaceutical Technology.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here